New drug trial aims to tame rare inflammatory disease in kids
NCT ID NCT07222553
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called inebilizumab in 15 children aged 2 to 17 who have IgG4-related disease, a rare condition that causes swelling and damage in organs. The drug is given through an IV and works by lowering certain immune cells to reduce inflammation. Researchers will check how the drug moves through the body, its safety, and whether it can prevent disease flares.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inebilizumab (a drug given by IV infusion that targets B-cells to reduce inflammation)
- What this could lead to
- If it works, this could provide a treatment option for children with IgG4-related disease, potentially reducing flares and the need for steroids.
- What could go wrong
- This is a small, early-phase trial with only 15 children, so results may not apply to all patients. The drug may cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN G4 RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.